The present invention relates generally to a shunt and a catheter having a system for reducing the risk of blockage or obstruction of the catheter apertures and also increases the ease of revision surgery if the catheter is removed.
Hydrocephalus is a neurological condition that is caused by the abnormal accumulation of cerebrospinal fluid (CSF) within the ventricles, or cavities, of the brain. CSF is a clear, colorless fluid that is primarily produced by the choroid plexus and surrounds the brain and spinal cord. CSF constantly circulates through the ventricular system of the brain and is ultimately absorbed into the bloodstream. CSF aids in the protection of the brain and spinal cord. Because CSF keeps the brain and spinal cord buoyant, it acts as a protective cushion or “shock absorber” to prevent injuries to the central nervous system.
Hydrocephalus, which affects children and adults, arises when the normal drainage of CSF in the brain is blocked in some way. Such blockage can be caused by a number of factors, including, for example, genetic predisposition, intraventricular or intracranial hemorrhage, infections such as meningitis, head trauma, or the like. Blockage of the flow of CSF consequently creates an imbalance between the amount of CSF produced by the choroid plexus and the rate at which CSF is absorbed into the bloodstream, thereby increasing pressure on the brain, which causes the ventricles to enlarge.
Hydrocephalus is most often treated by surgically inserting a shunt system that diverts the flow of CSF from the ventricle to another area of the body where the CSF can be absorbed as part of the circulatory system. Shunt systems come in a variety of models, and typically share similar functional components. These components include a ventricular catheter which is introduced through a burr hole in the skull and implanted in the patient's ventricle, a drainage catheter that carries the CSF to its ultimate drainage site, and optionally a flow-control mechanism, e.g., shunt valve, that regulates the one-way flow of CSF from the ventricle to the drainage site to maintain normal pressure within the ventricles. The ventricular catheter typically contains multiple holes or apertures positioned along the length of the ventricular catheter to allow the CSF to enter into the shunt system, as shown in
Shunting is considered one of the basic neurosurgical procedures, yet it has the highest complication rate. The most common complication with shunting is obstruction of the system. Although obstruction or clogging may occur at any point along the shunt system, it most frequently occurs at the ventricular end of the shunt system. While there are several ways that the ventricular catheter may become blocked or clogged, obstruction is typically caused by growth of tissue, such as the choroid plexus, around the catheter and into the apertures, as shown in
Some of these problems can be treated by backflushing, which is a process that uses the CSF present in the shunt system to remove the obstructing matter. This process can be ineffective, however, due to the small size of the apertures of the ventricular catheter and due to the small amount of flushing liquid available in the shunt system. Other shunt systems have been designed to include a mechanism for flushing the shunt system. For example, some shunt systems include a pumping device within the system which causes fluid in the system to flow with considerable pressure and velocity, thereby flushing the system. As with the process of backflushing, using a built-in mechanism to flush the shunt system can also fail to remove the obstruction due to factors such as the size of the apertures and the degree and extent to which the apertures have been clogged.
Occluded ventricular catheters can also be repaired by cauterizing the catheter to remove blocking tissue, thereby reopening existing apertures that have become occluded. Alternatively, new apertures can be created in the catheter. These repairs, however, may be incapable of removing obstructions from the ventricular catheter depending on the location of the clogged apertures. Additionally, the extent of tissue growth into and around the catheter can also preclude the creation of additional apertures, for example, in situations where the tissue growth covers a substantial portion of the ventricular catheter. Another disadvantage of creating new apertures to repair an occluded ventricular catheter is that this method fails to prevent or reduce the risk of repeated obstructions.
Because attempts at flushing or repairing a blocked ventricular catheter are often futile and ineffective, occlusion is more often treated by replacing the catheter. Although this can be accomplished by removing the obstructed catheter from the ventricle, the growth of the choroid plexus and other tissues around the catheter and into the apertures can hinder removal and replacement of the catheter. Care must be exercised to avoid damage to the choroid plexus, which can cause severe injury to the patient, such as, for example, hemorrhaging. Not only do these procedures pose a significant risk of injury to the patient, they can also be very costly, especially when shunt obstruction is a recurring problem.
Accordingly, there exists a need for a shunt and a ventricular catheter that minimizes or eliminates the risk of blockage or obstruction of the catheter apertures, that increases the ease of revision surgery if the catheter is removed and reduces the need for repeated repair and/or replacement.
The present invention provides a shunt that includes a housing having an inlet, an outlet and a flow control mechanism disposed within the housing. A ventricular catheter is connected to the inlet of the housing. The catheter has a longitudinal length, a proximal end, a distal end, and an inner lumen extending therethrough. The inner lumen of the catheter includes at least two lumens at the distal end and has only one lumen at the proximal end. The catheter has one aperture corresponding to each of the at least two lumens located at the distal end of the catheter.
Referring now to
As illustrated in
Ventricular catheter 12 has only one aperture 26 at distal end 22 of catheter 12 corresponding to each of the lumens 241, 24111, 241111, etc. There are preferably between 2 and 7 lumens, with only three and four lumens being shown in the drawing Figures for the sake of brevity. Of course, one skilled in the art would readily know how to make the ventricular catheter of the present invention with multiple lumens based on the present disclosure. Each tapering slit 30 receives cerebrospinal fluid (CSF) when in use. Each aperture 26 has an enlarged opening 28 at the distal end and transitions from the enlarged opening to a tapering slit 30 at the proximal end of the aperture. In some examples of the present invention, for each aperture 26, a portion 32 between the enlarged opening 28 and the tapering slit 30 is a slit 32 of constant thickness. Likewise, in other examples of the present invention, for each aperture 26, there may be no portion 32 between the enlarged opening 28 and the tapering slit 30. In addition, as illustrated in
The use of multiple lumens 241, 24111, 241111, etc. in accordance with the present invention help prevent complete occlusion of ventricular catheter 12. In the present invention, ventricular catheter 12 can only be completely occluded if all the lumens become blocked. In addition, because the transition from multiple lumens to a single lumen 24 occurs from about 0.5 to about 3.0 centimeters from the distal end of the ventricular catheter, any ingrowth of choroid plexus or ependymal tissue must extend beyond this junction to cause complete occlusion and interconnection of tissue from multiple apertures, which is unlikely to happen because of the length the tissue has to grow. The only other way that the choroid plexus or ependymal tissue would cause a complete occlusion is for the tissue to block each of the multiple lumens 24 beyond the slit 30, or to occlude the entire slit 30 and the aperture 26.
The slit lumen geometry is preferably tapered or purposely shaped to provide resistance to fluid flow through the slit that corresponds to the size of the pathway provided by the slit. The size of the slit opening distributes the pressure gradient over a larger distance and surface area than conventional ventricular catheters. Diffusing the pressure gradient diminishes the attractive fluid forces and diminishes areas of high fluid flow, thereby lessens the propensity for tissue ingrowth.
Referring now to
Referring now to
It will be understood that the foregoing is only illustrative of the principles of the invention, and that various modifications can be made by those skilled in the art without departing from the scope and spirit of the invention. All references cited herein are expressly incorporated by reference in their entirety.
The present application is a continuation of U.S. application Ser. No. 12/894,111 filed Sep. 29, 2010.
Number | Name | Date | Kind |
---|---|---|---|
4182343 | Inaba | Jan 1980 | A |
4375816 | Labianca | Mar 1983 | A |
4377169 | Banks | Mar 1983 | A |
4398910 | Blake | Aug 1983 | A |
4406656 | Hattler | Sep 1983 | A |
4465481 | Blake | Aug 1984 | A |
4465482 | Tittel | Aug 1984 | A |
4610671 | Luther | Sep 1986 | A |
4655745 | Corbett | Apr 1987 | A |
4767400 | Miller | Aug 1988 | A |
4795439 | Guest | Jan 1989 | A |
4863441 | Lindsay | Sep 1989 | A |
4950232 | Ruzicka | Aug 1990 | A |
4961729 | Vaillancourt | Oct 1990 | A |
4973319 | Melsky | Nov 1990 | A |
5116310 | Seder | May 1992 | A |
5201723 | Quinn | Apr 1993 | A |
5207684 | Nobles | May 1993 | A |
5360414 | Yarger | Nov 1994 | A |
5405316 | Magram | Apr 1995 | A |
5531673 | Helenowski | Jul 1996 | A |
5776096 | Fields | Jul 1998 | A |
6582388 | Coleman | Jun 2003 | B1 |
6821265 | Bertolero | Nov 2004 | B1 |
6866657 | Shchervinsky | Mar 2005 | B2 |
6893424 | Shchervinsky | May 2005 | B2 |
7037288 | Rosenberg | May 2006 | B2 |
7090672 | Underwood | Aug 2006 | B2 |
7094214 | Dextradeur | Aug 2006 | B2 |
7195608 | Burnett | Mar 2007 | B2 |
7207965 | Simon | Apr 2007 | B2 |
7223263 | Seno | May 2007 | B1 |
7226441 | Kulessa | Jun 2007 | B2 |
7604658 | Wilson | Oct 2009 | B2 |
7959623 | Massengale | Jun 2011 | B2 |
20030135148 | Dextradeur | Jul 2003 | A1 |
20030236483 | Ren | Dec 2003 | A1 |
20050159697 | Dextradeur | Jul 2005 | A1 |
20050251144 | Wilson | Nov 2005 | A1 |
20090118661 | Moehle | May 2009 | A1 |
20090254062 | McGlothlin | Oct 2009 | A1 |
20110172590 | Akahoshi | Jul 2011 | A1 |
Number | Date | Country |
---|---|---|
3033459 | Apr 1982 | DE |
1712252 | Oct 2006 | EP |
2089215 | Jun 1982 | GB |
2002-224222 | Aug 2002 | JP |
Entry |
---|
U.S. Appl. No. 12/894,111, Non-Final Rejection dated Oct. 18, 2013. |
U.S. Appl. No. 12/894,111, Non-Final Rejection dated Mar. 22, 2012. |
U.S. Appl. No. 12/894,111, Final Rejection dated Jul. 20, 2012. |
Number | Date | Country | |
---|---|---|---|
20140228734 A1 | Aug 2014 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 12894111 | Sep 2010 | US |
Child | 14182997 | US |